- Home
- ATHA vs ALLR Comparison
ATHA vs ALLR Comparison
Compare ATHA & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- ALLR
- Stock Information
- Founded
- ATHA 2011
- ALLR 2004
- Country
- ATHA United States
- ALLR United States
- Employees
- ATHA N/A
- ALLR N/A
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- ATHA Health Care
- ALLR Health Care
- Exchange
- ATHA Nasdaq
- ALLR Nasdaq
- Market Cap
- ATHA 18.2M
- ALLR 20.2M
- IPO Year
- ATHA 2020
- ALLR N/A
- Fundamental
- Price
- ATHA $4.72
- ALLR $1.30
- Analyst Decision
- ATHA
- ALLR Strong Buy
- Analyst Count
- ATHA 0
- ALLR 1
- Target Price
- ATHA N/A
- ALLR $9.25
- AVG Volume (30 Days)
- ATHA 25.6K
- ALLR 203.6K
- Earning Date
- ATHA 11-06-2025
- ALLR 11-14-2025
- Dividend Yield
- ATHA N/A
- ALLR N/A
- EPS Growth
- ATHA N/A
- ALLR N/A
- EPS
- ATHA N/A
- ALLR N/A
- Revenue
- ATHA N/A
- ALLR N/A
- Revenue This Year
- ATHA N/A
- ALLR N/A
- Revenue Next Year
- ATHA N/A
- ALLR N/A
- P/E Ratio
- ATHA N/A
- ALLR N/A
- Revenue Growth
- ATHA N/A
- ALLR N/A
- 52 Week Low
- ATHA $2.20
- ALLR $0.61
- 52 Week High
- ATHA $6.79
- ALLR $2.35
- Technical
- Relative Strength Index (RSI)
- ATHA 61.31
- ALLR 53.02
- Support Level
- ATHA $4.31
- ALLR $0.99
- Resistance Level
- ATHA $4.95
- ALLR $1.17
- Average True Range (ATR)
- ATHA 0.37
- ALLR 0.10
- MACD
- ATHA -0.04
- ALLR 0.02
- Stochastic Oscillator
- ATHA 73.60
- ALLR 93.89
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.